US Edition
Dosing begins in Parkinson’s clinical trial of brain-penetrant therapy
Summary by Parkinson's News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Dosing begins in Parkinson’s clinical trial of brain-penetrant therapy
The first patient has been dosed in a pivotal Phase 2/3 clinical trial testing BHV-8000, a brain-penetrant oral small molecule that Biohaven Therapeutics is developing as a disease-modifying therapy for neuroinflammatory conditions, including Parkinson’s disease. The clinical trial (NCT06976268) is evaluating the effectiveness and safety of BHV-8000 in individuals with early Parkinson’s disease. Specifically, it aims to determine whether daily d…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
